[go: up one dir, main page]

PE20020854A1 - SULFONAMIDA LACTAMA COMO INHIBIDORES DEL FACTOR Xa - Google Patents

SULFONAMIDA LACTAMA COMO INHIBIDORES DEL FACTOR Xa

Info

Publication number
PE20020854A1
PE20020854A1 PE2002000071A PE2002000071A PE20020854A1 PE 20020854 A1 PE20020854 A1 PE 20020854A1 PE 2002000071 A PE2002000071 A PE 2002000071A PE 2002000071 A PE2002000071 A PE 2002000071A PE 20020854 A1 PE20020854 A1 PE 20020854A1
Authority
PE
Peru
Prior art keywords
alkyl
alkenyl
heteroaryl
aryl
cycloalkyl
Prior art date
Application number
PE2002000071A
Other languages
English (en)
Inventor
Stephen P O'connor
R Michael Lawrence
Yan Shi
Philip P Stein
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of PE20020854A1 publication Critical patent/PE20020854A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Emergency Medicine (AREA)

Abstract

SE REFIERE A COMPUESTOS SULFONAMIDA LACTAMA DE FORMULA I DONDE X ES -(CH2)m- OPCIONALMENTE SUSTITUIDO CON OXO, ALQUILO, ARIL; m ES 1-3; R1 ES ALQUILO, ALQUENILO, ALQUINILO, CICLOALQUILO, ARILO, CICLOHETEROALQUILO, HETEROARILO, CICLOHETEROALQUILO, R2 Y R3 SON H, ALQUILO, ALQUENILO, ALQUINILO, CICLOALQUILO, ARILO, CICLOHETEROALQUILO, HETEROARILO; R4, R4a, R5, R5a SON H, ALQUILO, ALQUENILO, ALQUINILO, CICLOALQUILO, ARILO, HETEROARILO, CICLOHETEROARILO, HIDROXI, ALCOXI, CORa, NRa-SO2Rb, R6 Y R6a SON H, ALQUILO, ALQUENILO, ALQUINILO, CICLOALQUILO, ARILO, HETEROARILO, CICLOHETEROARILO; R7 Y R8 SON (CH2)n-H; n ES 1-4, O JUNTO A N FORMAN CICLOHETEROALQUILO; Ra Y Rb SON H, ALQUILO, ALQUENILO, ALQUINILO, ARILO, HETEROARILO, ENTRE OTROS; EXCEPTO COMPUESTOS DE FORMULA X, R1a ES ALQUILO, ARILO, ALQUILO, ALQUENILO, ENTRE OTROS; R7a ES ALQUILO, R8a ES UN GRUPO a; p ES 1-3; W Y W* SON CH, N; TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE ADEMAS ESTREPTOCINASA, RELEPLASA, ACTIVASA, LANOTEPLASA, UROCINASA, PROUROCINASA, WARFARINA, CLOPIDOGREL, ASPIRINA, TICLOPIDINA, IFETROBAN, DIPIRIDAMOL, CILOSTAZOL, PICOTAMIDA, KETANSERINA. LOS COMPUESTOS SON INHIBIDORES DE SERINA PROTEASA DE LA COAGULACION ACTIVADA O FACTOR Xa, ACTUAN COMO ANTICOAGULANTES Y PUEDEN SER UTILES PARA EL TRATAMIENTO DE PADECIMIENTOS CARDIOVASCULARES ASOCIADOS CON LA TROMBOSIS ARTERIAL, PADECIMIENTOS VASCULARES CEREBRALES
PE2002000071A 2001-01-30 2002-01-30 SULFONAMIDA LACTAMA COMO INHIBIDORES DEL FACTOR Xa PE20020854A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US26496401P 2001-01-30 2001-01-30

Publications (1)

Publication Number Publication Date
PE20020854A1 true PE20020854A1 (es) 2002-09-27

Family

ID=23008391

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2002000071A PE20020854A1 (es) 2001-01-30 2002-01-30 SULFONAMIDA LACTAMA COMO INHIBIDORES DEL FACTOR Xa

Country Status (8)

Country Link
US (2) US6555542B1 (es)
EP (1) EP1358178A2 (es)
JP (1) JP2004518688A (es)
CA (1) CA2436774A1 (es)
HU (1) HUP0304058A2 (es)
PE (1) PE20020854A1 (es)
UY (1) UY27143A1 (es)
WO (1) WO2002060894A2 (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
JP2004532854A (ja) * 2001-05-10 2004-10-28 アグロン ファ−マシュ−テイカルズ インコ−ポレイテッド 複素２環式ｆｋｂｐリガンド
GB0114005D0 (en) 2001-06-08 2001-08-01 Glaxo Group Ltd Chemical compounds
GB0114004D0 (en) 2001-06-08 2001-08-01 Glaxo Group Ltd Chemical compounds
EP1448553B1 (en) * 2001-10-04 2005-05-04 Ortho McNeil Pharmaceutical, Inc. N-heterocyclyl hydrazides as neurotrophic agents
CA2523157A1 (en) * 2003-04-24 2004-11-04 Boehringer Ingelheim International Gmbh Use of dipyridamole or mopidamole for treatment and prevention of thrombo-embolic diseases and disorders caused by excessive formation of thrombin and/or by elevated expression ofthrombin receptors
WO2005030740A1 (ja) * 2003-09-30 2005-04-07 Takeda Pharmaceutical Company Limited チアゾリン誘導体およびその用途
EP1750862B1 (en) 2004-06-04 2011-01-05 Teva Pharmaceutical Industries Ltd. Pharmaceutical composition containing irbesartan
EP1807086A1 (en) * 2004-10-25 2007-07-18 Boehringer Ingelheim International GmbH Use of dipyridamole in combination with antithrombotics for treatment and prevention of thromboembolic diseases
EP1724269A1 (en) * 2005-05-20 2006-11-22 Sanofi-Aventis Deutschland GmbH Heteroaryl-carboxylic acid (sulfamoyl alkyl) amide - derivatives as factor Xa inhibitors
EP1818330A1 (de) * 2006-02-14 2007-08-15 Boehringer Ingelheim Pharma GmbH & Co.KG Substituierte Prolinamide, deren Herstellung und deren Verwendung als Arzneimittel
US20110165236A1 (en) * 2006-09-22 2011-07-07 Biokey, Inc. Controlled release hydrogel formulation
US20080075785A1 (en) * 2006-09-22 2008-03-27 San-Laung Chow Controlled release hydrogel formulation
ES2466346T3 (es) * 2006-10-02 2014-06-10 Techfields Biochem Co. Ltd Profármacos de prostaglandinas solubles en agua con carga positiva y compuestos relacionados con índices de penetración en la piel muy altos
DE102007008484A1 (de) * 2007-02-19 2008-08-21 Epo Experimentelle Pharmakologie & Onkologie Berlin-Buch Gmbh Pharmazeutische Zubereitung zur Bekämpfung von Metastasen
EP2558458B1 (de) 2010-04-16 2017-09-06 Bayer Intellectual Property GmbH Neue heterocyclische verbindungen als schädlingsbekämpfungsmittel
JO2998B1 (ar) 2010-06-04 2016-09-05 Amgen Inc مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان
CN102464701B (zh) * 2010-11-08 2015-10-21 上海医药工业研究院 一类新型化合物、其制备方法及用途
JP6093770B2 (ja) 2011-09-27 2017-03-08 アムジエン・インコーポレーテツド 癌の治療のためのｍｄｍ２阻害剤としての複素環化合物
US11407721B2 (en) 2013-02-19 2022-08-09 Amgen Inc. CIS-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer
AU2014223547B2 (en) 2013-02-28 2017-11-16 Amgen Inc. A benzoic acid derivative MDM2 inhibitor for the treatment of cancer
JP6377123B2 (ja) 2013-03-14 2018-08-22 アムジエン・インコーポレーテツド 癌の治療のためのｍｄｍ２阻害剤としてのヘテロアリール酸モルホリノン化合物
JOP20200296A1 (ar) 2013-06-10 2017-06-16 Amgen Inc عمليات صنع وأشكال بلورية من mdm2 مثبط
US9676723B2 (en) 2014-02-11 2017-06-13 Merck Sharp & Dohme Corp Factor XIa inhibitors
EP3104703B1 (en) 2014-02-11 2020-11-18 Merck Sharp & Dohme Corp. Factor xia inhibitors
US10093683B2 (en) 2014-04-22 2018-10-09 Merck Sharp & Dohme Corp. Factor XIa inhibitors
EP3180317B1 (en) 2014-07-28 2021-04-14 Merck Sharp & Dohme Corp. FACTOR XIa INHIBITORS
CN108430471B (zh) 2015-10-29 2021-07-09 默沙东公司 因子XIa抑制剂
US10344039B2 (en) 2015-10-29 2019-07-09 Merck Sharp & Dohme Corp. Macrocyclic spirocarbamate derivatives as factor XIa inhibitors, pharmaceutically acceptable compositions and their use
US11154558B2 (en) * 2016-04-15 2021-10-26 Adams Pharmaceuticals LLC Prevention of atherosclerotic events with direct factor Xa inhibitors
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists
TW201808908A (zh) 2016-08-22 2018-03-16 美商默沙東藥廠 因子XIa抑制劑

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA893284B (en) 1988-05-04 1990-03-28 Igen Inc Peptide analogs and their use as haptens to elicit catalytic antibodies
IL92011A0 (en) 1988-10-19 1990-07-12 Abbott Lab Heterocyclic peptide renin inhibitors
US5164388A (en) 1988-10-19 1992-11-17 Abbott Laboratories Heterocyclic peptide renin inhibitors
EP0444156A4 (en) 1988-11-21 1992-12-09 Abbott Laboratories Method for treating vascular diseases
DE4035961A1 (de) 1990-11-02 1992-05-07 Thomae Gmbh Dr K Cyclische iminoderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
DE4038921A1 (de) 1990-12-06 1992-06-11 Bayer Ag Renininhibitorische peptide vom cyclohexylstatin-typ, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln
DE4038947A1 (de) 1990-12-06 1992-06-11 Bayer Ag Dithiolano- und dithianoglycin-haltige renininhibitorische peptide, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln
PL294870A1 (es) 1991-06-21 1993-02-08 Hoechst Ag
DE4121947A1 (de) 1991-07-03 1993-01-07 Basf Ag 2-(3-(4-amidino-phenyl))-propionsaeurederivate, ihre herstellung und verwendung
ATE196296T1 (de) 1992-12-16 2000-09-15 Basf Ag Dolastatin analog
JPH10503176A (ja) 1994-06-17 1998-03-24 コーバス インターナショナル， インコーポレイテッド 酵素インヒビターとしての３−アミノ−２−オキソ−１−ピペリジン酢酸誘導体
US5703208A (en) 1994-06-17 1997-12-30 Corvas International, Inc. 3-amino-2-oxo-1-piperidineacetic derivatives as enzyme inhibitors
US5714499A (en) 1994-06-17 1998-02-03 Corvas International, Inc. 3-amino-2-oxo-1-piperidineacetic derivatives containing an arginine mimic as enzyme inhibitors
US5932733A (en) 1994-06-17 1999-08-03 Corvas International, Inc. 3-amino-2-oxo-1-piperidineacetic derivatives containing an arginine mimic as enzyme inhibitors
US5612353A (en) 1995-06-07 1997-03-18 Rhone-Poulenc Rorer Pharmaceuticals Inc. Substituted (sulfinic acid, sulfonic acid, sulfonylamino or sulfinylamino) N-[(aminoiminomethyl)phenylalkyl]-azaheterocyclylamide compounds
DK0859784T3 (da) 1995-10-05 2003-04-22 Darwin Discovery Ltd Thiosubstituerede peptider som inhibitorer af metalloproteinaser og TNF-frigivelse
JPH09165370A (ja) 1995-10-13 1997-06-24 Fuji Yakuhin Kogyo Kk ラクタム誘導体およびその塩
AU713247B2 (en) 1995-10-19 1999-11-25 Merck & Co., Inc. Fibrinogen receptor antagonists
US5719296A (en) 1995-10-30 1998-02-17 Merck & Co., Inc. Pseudopeptide lactam inhibitors of peptide binding to MHC class II proteins
WO1997024339A1 (en) 1995-12-27 1997-07-10 Ono Pharmaceutical Co., Ltd. Tetrazole derivatives and drugs containing the same as the active ingredient
CZ291690B6 (cs) 1996-02-13 2003-05-14 Akzo Nobel N. V. Inhibitory serinové proteázy a farmaceutický prostředek
TW442452B (en) 1996-03-01 2001-06-23 Akzo Nobel Nv Serine protease inhibitors having an alkynylamino side chain
TW523513B (en) 1996-03-01 2003-03-11 Akzo Nobel Nv Serine protease inhibitors
EP0912513A1 (en) 1996-06-28 1999-05-06 Merck & Co., Inc. Fibrinogen receptor antagonist prodrugs
CA2263999A1 (en) 1996-08-29 1998-03-05 Merck & Co., Inc. Integrin antagonists
WO1998016523A2 (en) 1996-10-11 1998-04-23 Cor Therapeutics, Inc. Selective factor xa inhibitors
US6281227B1 (en) 1996-12-13 2001-08-28 Aventis Pharma Deutschland Gmbh Sulfonic acid sulfonylamino n-(heteroaralkyl)-azaheterocyclylamide compounds
AU7105498A (en) 1997-04-14 1998-11-11 Merck & Co., Inc. Combination therapy for the prevention and treatment of osteoporosis
IL123986A (en) 1997-04-24 2011-10-31 Organon Nv Medicinal compounds
PL336589A1 (en) 1997-05-02 2000-07-03 Akzo Nobel Nv Serinic protease inhibitors
US6787612B1 (en) 1998-07-24 2004-09-07 Dendreon Corporation Resin derivatization method and uses thereof
CA2361479A1 (en) 1999-01-27 2000-08-03 Ortho-Mcneil Pharmaceutical, Inc. Peptidyl heterocyclic ketones useful as tryptase inhibitors
MXPA02002657A (es) 1999-09-13 2002-10-28 Dimensional Pharm Inc Inhibidores de azacicloalcanona serina proteasa.

Also Published As

Publication number Publication date
CA2436774A1 (en) 2002-08-08
EP1358178A2 (en) 2003-11-05
US20040186134A1 (en) 2004-09-23
JP2004518688A (ja) 2004-06-24
US7166586B2 (en) 2007-01-23
HUP0304058A2 (hu) 2004-04-28
WO2002060894A3 (en) 2002-12-19
UY27143A1 (es) 2002-08-30
WO2002060894A2 (en) 2002-08-08
US6555542B1 (en) 2003-04-29

Similar Documents

Publication Publication Date Title
PE20020854A1 (es) SULFONAMIDA LACTAMA COMO INHIBIDORES DEL FACTOR Xa
AR038240A1 (es) Compuesto de piperidina, uso del mismo para la fabricacion de un medicamento, composicion farmaceutica que lo comprende y procedimiento para su preparacion
CO5540344A2 (es) Medicamentos
PE20040071A1 (es) Indazoles substituidos, composiciones que los contienen, procedimiento de fabricacion y utilizacion
PE20021089A1 (es) Compuestos de triazol como inhibidores de las citoquinas
AR031556A1 (es) Derivados de 3-(diarilmetilen)-8-azabiciclo[3.2.1] octano y composiciones farmaceuticas que los comprenden
NO20073729L (no) Heterocykliske forbindelser som CCR2B-antagonister
PA8591701A1 (es) Derivados de pirrolopirimidina
AR046711A1 (es) 5-7-diaminopirazolo[4,3d]pirimidinas como inhibidores de la pde-5,composiciones farmaceuticas que las contienen y usos en el tratamiento de hipertensiones
NO20060973L (no) Pyridylderivater og deres anvendelse som tempeutiske midler
ES2080900T3 (es) Derivados piranicos utiles como inhibidores de 5-lipoxigenasa.
PE20141681A1 (es) Inhibidores de btk
AR050181A1 (es) Derivados de urea ciclicos sustituidos, su preparacion y su uso farmaceutico como inhibidores de quinasa
PE20090042A1 (es) Analogos de ciclopamina
PE20050867A1 (es) DERIVADOS DE PIPERAZINA COMO INHIBIDORES DE LA INTERACCION DE gp 120 CON CD4
AR033989A1 (es) Un compuesto derivado de la 3-indolil-4-fenil-1h-pirrol-2,5-diona, un metodo para prepararlo, y un medicamento que lo contiene
ES2092316T3 (es) Agentes antianginosos de purinona.
PE20001037A1 (es) Compuestos heterociclicos como inhibidores de enzimas de rotamasa
CO5611143A2 (es) Profarmacos de fosfatos de fluorooxindoles
AR058587A1 (es) Compuestos de pirrolo-1,5-naftiridinona,su uso como agentes antibacterianos, composiciones farmaceuticas que los contienen y compuestos intermediarios para preparar dichos compuestos
PA8495101A1 (es) Derivados de 13-metileritromicina
AR030203A1 (es) Derivados de carbamato de 2-(s)-hidroximutilina, composiciones farmaceuticas que los comprenden, procedimiento para prepararlos y 2(s), 11-dihidroxi protegida-mutilina como compuesto intermediario
DE60142838D1 (de) Pharmazeutisch aktive benzsulfonamidderivate als inhibitoren von protein-jun-kinasen
CO4970744A1 (es) Caspasas y apoptosis
ES2291722T3 (es) Aminoalcoxiindoles como ligandos 5-ht6-receptores para el tratamiento de transtornos del snc.

Legal Events

Date Code Title Description
FC Refusal